Jérôme Courcambeck

666 total citations
24 papers, 454 citations indexed

About

Jérôme Courcambeck is a scholar working on Infectious Diseases, Epidemiology and Organic Chemistry. According to data from OpenAlex, Jérôme Courcambeck has authored 24 papers receiving a total of 454 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 10 papers in Epidemiology and 8 papers in Organic Chemistry. Recurrent topics in Jérôme Courcambeck's work include HIV/AIDS drug development and treatment (12 papers), Hepatitis C virus research (7 papers) and Hepatitis B Virus Studies (6 papers). Jérôme Courcambeck is often cited by papers focused on HIV/AIDS drug development and treatment (12 papers), Hepatitis C virus research (7 papers) and Hepatitis B Virus Studies (6 papers). Jérôme Courcambeck collaborates with scholars based in France, United States and Belgium. Jérôme Courcambeck's co-authors include Philippe Halfon, Jérôme Deval, Boulbaba Selmi, Bruno Canard, Joëlle Boretto, Neil Parkin, Michael D. Miller, Kirsten White, Gérard Pèpe and Joséphine Sire and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Jérôme Courcambeck

23 papers receiving 444 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jérôme Courcambeck France 12 261 204 132 102 89 24 454
Satoki Doi Japan 6 273 1.0× 234 1.1× 186 1.4× 57 0.6× 100 1.1× 9 460
Alessia Petrocchi Italy 11 258 1.0× 146 0.7× 298 2.3× 92 0.9× 138 1.6× 18 561
Dawn D. Parker United States 13 203 0.8× 168 0.8× 154 1.2× 134 1.3× 137 1.5× 22 498
S. Benzaria France 11 370 1.4× 111 0.5× 335 2.5× 183 1.8× 139 1.6× 25 638
Christine Burlein United States 11 182 0.7× 61 0.3× 184 1.4× 98 1.0× 144 1.6× 18 449
Joan Zugay-Murphy United States 8 130 0.5× 103 0.5× 202 1.5× 44 0.4× 68 0.8× 9 363
Sanjeev Kumar V. Vernekar United States 13 246 0.9× 181 0.9× 235 1.8× 53 0.5× 271 3.0× 16 577
R Mathis United States 4 456 1.7× 245 1.2× 266 2.0× 168 1.6× 166 1.9× 4 596
Samantha Zanoli Italy 15 244 0.9× 193 0.9× 233 1.8× 101 1.0× 279 3.1× 23 618
Bart De Corte Belgium 8 261 1.0× 222 1.1× 129 1.0× 67 0.7× 148 1.7× 15 483

Countries citing papers authored by Jérôme Courcambeck

Since Specialization
Citations

This map shows the geographic impact of Jérôme Courcambeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jérôme Courcambeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jérôme Courcambeck more than expected).

Fields of papers citing papers by Jérôme Courcambeck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jérôme Courcambeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jérôme Courcambeck. The network helps show where Jérôme Courcambeck may publish in the future.

Co-authorship network of co-authors of Jérôme Courcambeck

This figure shows the co-authorship network connecting the top 25 collaborators of Jérôme Courcambeck. A scholar is included among the top collaborators of Jérôme Courcambeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jérôme Courcambeck. Jérôme Courcambeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brun, Sonia, Jean‐Marc Pascussi, Eloïne Bestion, et al.. (2021). GNS561, a New Autophagy Inhibitor Active against Cancer Stem Cells in Hepatocellular Carcinoma and Hepatic Metastasis from Colorectal Cancer. Journal of Cancer. 12(18). 5432–5438. 12 indexed citations
2.
Bestion, Eloïne, Zuzana Macek Jílková, Jean‐Louis Mège, et al.. (2020). GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition. Therapeutic Advances in Chronic Disease. 11. 1754233818–1754233818. 11 indexed citations
3.
Brun, Sonia, et al.. (2019). GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma. Investigational New Drugs. 37(6). 1135–1145. 25 indexed citations
4.
Lagaye, Sylvie, Sonia Brun, Jésintha Gaston, et al.. (2016). Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model. World Journal of Hepatology. 8(21). 902–902. 4 indexed citations
5.
Pradère, Ugo, Peng Liu, Chengwei Li, et al.. (2013). Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(23). 6325–6330. 17 indexed citations
6.
Courcambeck, Jérôme, et al.. (2011). 1210 GNS-227: A NEW POTENT AND SELECTIVE HCV NS3 PROTEASE INHIBITOR WITH A HIGH GENETIC BARRIER TO RESISTANCE. Journal of Hepatology. 54. S478–S478. 1 indexed citations
7.
Courcambeck, Jérôme, et al.. (2009). Prediction of molecular crystal structures using a genetic algorithm: Validation by GenMol™ on energetic compounds. Journal of Crystal Growth. 311(13). 3498–3510. 11 indexed citations
8.
Courcambeck, Jérôme, et al.. (2008). Prediction of HIV-1 protease inhibitor resistance by Molecular Modeling Protocols (MMPs) using GenMol™ software. European Journal of Medicinal Chemistry. 43(11). 2518–2534. 2 indexed citations
9.
Courcambeck, Jérôme, Besma Jouirou, P. Cacoub, et al.. (2006). Resistance of Hepatitis C Virus to Ns3–4A Protease Inhibitors: Mechanisms of Drug Resistance Induced by R155Q, A156T, D168A and D168V Mutations. Antiviral Therapy. 11(7). 847–856. 48 indexed citations
10.
11.
Barral, Karine, Jérôme Courcambeck, Gérard Pèpe, et al.. (2004). Synthesis and Antiviral Evaluation of Cis-Substituted Cyclohexenyl and Cyclohexanyl Nucleosides. Journal of Medicinal Chemistry. 48(2). 450–456. 31 indexed citations
12.
Deval, Jérôme, Jean‐Marc Navarro, Boulbaba Selmi, et al.. (2004). A Loss of Viral Replicative Capacity Correlates with Altered DNA Polymerization Kinetics by the Human Immunodeficiency Virus Reverse Transcriptase Bearing the K65R and L74V Dideoxynucleoside Resistance Substitutions. Journal of Biological Chemistry. 279(24). 25489–25496. 71 indexed citations
13.
Deval, Jérôme, et al.. (2004). Structural Determinants and Molecular Mechanisms for the Resistance of HIV-1 RT to Nucleoside Analogues. Current Drug Metabolism. 5(4). 305–316. 23 indexed citations
14.
Deval, Jérôme, Kirsten White, Michael D. Miller, et al.. (2003). Mechanistic Basis for Reduced Viral and Enzymatic Fitness of HIV-1 Reverse Transcriptase Containing Both K65R and M184V Mutations. Journal of Biological Chemistry. 279(1). 509–516. 123 indexed citations
15.
Halfon, Philippe, S. Pol, Marc Bourlière, Jérôme Courcambeck, & P. Cacoub. (2003). Résistance aux analogues de nucléosides dans le traitement de l’hépatite chronique B. La Revue de Médecine Interne. 24(12). 786–793.
16.
Bihel, Frédéric, et al.. (2002). Synthesis and Antiviral Activity of New Anti-HIV Amprenavir Bioisosteres. Journal of Medicinal Chemistry. 45(15). 3321–3324. 15 indexed citations
17.
Courcambeck, Jérôme, et al.. (2001). Design of potential new HIV protease inhibitors: enantioconvergent synthesis of new pyrrolidin-3-ol, and pyrrolidin-3-one peptide conjugates. Journal of the Chemical Society Perkin Transactions 1. 1421–1430. 26 indexed citations
18.
Courcambeck, Jérôme, et al.. (2000). Synthesis and chemical reactivity of thiophenoxyphenylalanine bioisosteres, suitable synthons for the design of HIV protease inhibitors. Journal of the Chemical Society Perkin Transactions 1. 819–824. 5 indexed citations
19.
Courcambeck, Jérôme, et al.. (2000). use of proline bioisosteres in potential HIV protease inhibitors: phenylalanine-2-thiophenoxy-3-pyrrolidinone: synthesis and anti-HIV evaluation. Bioorganic & Medicinal Chemistry Letters. 10(17). 2023–2026. 12 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Satoki Doi Breakdown of academic impact, for papers by Alessia Petrocchi Breakdown of academic impact, for papers by Dawn D. Parker Breakdown of academic impact, for papers by S. Benzaria Breakdown of academic impact, for papers by Christine Burlein Breakdown of academic impact, for papers by Joan Zugay-Murphy Breakdown of academic impact, for papers by Sanjeev Kumar V. Vernekar Breakdown of academic impact, for papers by R Mathis Breakdown of academic impact, for papers by Samantha Zanoli Breakdown of academic impact, for papers by Bart De Corte
Rankless by CCL
2026